Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Rallybio Corp (RLYB) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates"
05/09/2023 8-K Quarterly results
Docs: "Rallybio Reports First Quarter 2023 Financial Results -- RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31st Congress of the International Society of Thrombosis and Haemostasis in June 2023 -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated in 1Q 2023; Data Expected in 4Q 2023 -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $150.4 million cash, cash equivalents and marketable securities as of March 31, 2023; Provides Runway into 1Q 2025 --"
03/06/2023 8-K Quarterly results
Docs: "Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects – -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025-- NEW HAVEN, Conn. March 6, 2023-- Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the fourth qu...",
"Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia -- RLYB212 Showed Rapid Elimination of Transfused, HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Clinical Findings and Safety Profile Consistent with Previously Reported Data; Continue to Support the Potential for RLYB212 as a Prophylactic Treatment for FNAIT -- -- Company Expects to Present Results at a Scientific Conference in 2023 --"
11/07/2022 8-K Quarterly results
Docs: "Rallybio Reports Third Quarter 2022 Financial Results -- Preliminary results from Phase 1b study of RLYB212 showed rapid and complete elimination of transfused platelets in all subjects to date; Proof-of-concept data expected in 1Q 2023 -- -- Positive 100 mg results of Phase 1study of RLYB116 showed reduction of >99% in free C5 with the potential for weekly or less frequent dosing -- NEW HAVEN, Conn. November 7, 2022-- Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent program and corporate developments. “We made tremendous progre..."
08/08/2022 8-K Quarterly results
Docs: "Rallybio Reports Second Quarter 2022 Financial Results -- Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets -- -- Phase 1study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected for the 30 mg dose in the 4Q 2022-- NEW HAVEN, Conn. August 8, 2022-- Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent program and corporate developments. “We continue to progress our pipeline toward planned upcoming milestones. We are pleased to see that the emergi..."
05/10/2022 8-K Quarterly results
03/15/2022 8-K Quarterly results
Docs: "Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results -- Phase 1b proof-of-concept study for RLYB212 in development for the prevention of FNAIT on track to commence in 2Q 2022; initial data expected in 3Q 2022 -- -- First healthy volunteers dosed in Phase 1study of RLYB116; single dose safety, PK, and PD data expected in 2H 2022 -- -- Advancing preclinical development of ENPP1 inhibitor; IND-enabling studies expected to initiate in 2H 2022 --"
11/10/2021 8-K Quarterly results
Docs: "Rallybio Corporation Reports Third Quarter 2021 Financial Results and Recent Business Highlights -- Initiated FNAIT natural history study to inform frequency of FNAIT risk in broad population and support future potential registration trial -- -- On-track to announce in 4Q 2021 additional clinical data from ongoing Phase 1/2 study of RLYB211 for prevention of FNAIT -- -- Executing across preclinical portfolio, with Phase 1studies for RLYB212 and RLYB116 expected to initiate in 1Q 2022 --"
09/09/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy